Clinical Trial Update: Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma [Phase 1]

View source ↗

Summary

Phase 1 study assessing the combination of RAD001 (everolimus) and sorafenib in patients with advanced hepatocellular carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• RAD001 (Everolimus) (everolimus)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hepatocellular Carcinoma | Phase 1 | Status: TERMINATED